BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12787910)

  • 1. The radioenhancement of two human head and neck squamous cell carcinomas by 2'-2' difluorodeoxycytidine (gemcitabine; dFdC) is mediated by an increase in radiation-induced residual chromosome aberrations but not residual DNA DSBs.
    Rosier JF; Michaux L; Ameye G; Cedervall B; Libouton JM; Octave-Prignot M; Verellen-Dumoulin C; Scalliet P; Grégoire V
    Mutat Res; 2003 Jun; 527(1-2):15-26. PubMed ID: 12787910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of 2'-2' difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity.
    Rosier JF; Beauduin M; Bruniaux M; de Bast M; de Coster B; Octave-Prignot M; Scalliet P; Grégoire V
    Int J Radiat Biol; 1999 Feb; 75(2):245-51. PubMed ID: 10072186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresis.
    Grégoire V; Beauduin M; Bruniaux M; De Coster B; Octave Prignot M; Scalliet P
    Int J Radiat Biol; 1998 May; 73(5):511-20. PubMed ID: 9652808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of 2'-2' difluorodeoxycytidine (gemcitabine)-induced cell cycle dysregulation in radio-enhancement of human head and neck squamous cell carcinomas.
    Rosier JF; Bruniaux M; Husson B; Octave-Prignot M; Beauduin M; Grégoire V
    Radiother Oncol; 2004 Jan; 70(1):55-61. PubMed ID: 15036853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant increase in residual DNA damage as a possible mechanism of radiosensitization by gemcitabine.
    Weiss C; Grabenbauer GG; Sauer R; Distel L
    Strahlenther Onkol; 2003 Feb; 179(2):93-8. PubMed ID: 12590319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines.
    van Bree C; Castro Kreder N; Loves WJ; Franken NA; Peters GJ; Haveman J
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):237-44. PubMed ID: 12182997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of gemcitabine on cell survival and chromosome aberrations after pulsed low dose-rate irradiation.
    Castro Kreder N; Van Bree C; Franken NA; Haveman J
    J Radiat Res; 2004 Mar; 45(1):111-8. PubMed ID: 15133298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The intensification of the radiotherapeutic effect on HeLa cells by gemcitabine].
    Mose S; Karapetian M; Jüling-Pohlit L; Taborski B; Ramm U; Damrau M; Rahn A; Böttcher HD
    Strahlenther Onkol; 1999 Feb; 175(2):78-83. PubMed ID: 10065143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells.
    Grégoire V; Beauduin M; Rosier JF; De Coster B; Bruniaux M; Octave-Prignot M; Scalliet P
    Br J Cancer; 1997; 76(10):1315-21. PubMed ID: 9374377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanistic study of radiosensitization by gemcitabine on human squamous carcinoma cell line of the cervix].
    Miao JW; Kong WM; Zhang WH; Niu JW; Deng XH
    Zhonghua Fu Chan Ke Za Zhi; 2004 May; 39(5):342-5. PubMed ID: 15196420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colour junctions as predictors of radiosensitivity: X-irradiation combined with gemcitabine in a lung carcinoma cell line.
    Castro Kreder N; Van Bree C; Franken NA; Haveman J
    J Cancer Res Clin Oncol; 2003 Oct; 129(10):597-603. PubMed ID: 14513371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines.
    Mose S; Karapetian M; Jüling-Pohlit L; Taborski B; Damrau M; Ramm U; Rahn A; Böttcher HD
    Anticancer Res; 2000; 20(1A):401-5. PubMed ID: 10769687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation enhancement by gemcitabine-mediated cell cycle modulations.
    Mose S; Class R; Weber HW; Rahn A; Brady LW; Böttcher HD
    Am J Clin Oncol; 2003 Feb; 26(1):60-9. PubMed ID: 12576927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective targeting of homologous DNA recombination repair by gemcitabine.
    Wachters FM; van Putten JW; Maring JG; Zdzienicka MZ; Groen HJ; Kampinga HH
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):553-62. PubMed ID: 12957269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interaction between cisplatin and gemcitabine in vitro.
    Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
    Clin Cancer Res; 1996 Mar; 2(3):521-30. PubMed ID: 9816199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro.
    Grégoire V; Rosier JF; De Bast M; Bruniaux M; De Coster B; Octave-Prignot M; Scalliet P
    Radiother Oncol; 2002 Jun; 63(3):329-38. PubMed ID: 12142097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between cisplatin and gemcitabine in vitro and in vivo.
    Peters GJ; Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Braakhuis BJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):72-9. PubMed ID: 7481849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The extreme radiosensitivity of the squamous cell carcinoma SKX is due to a defect in double-strand break repair.
    Kasten-Pisula U; Menegakis A; Brammer I; Borgmann K; Mansour WY; Degenhardt S; Krause M; Schreiber A; Dahm-Daphi J; Petersen C; Dikomey E; Baumann M
    Radiother Oncol; 2009 Feb; 90(2):257-64. PubMed ID: 19038467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells.
    van Bree C; Rodermond H; Leen R; Medema J; van Kuilenburg A
    Br J Cancer; 2008 Apr; 98(7):1226-33. PubMed ID: 18349845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatch repair proficiency is not required for radioenhancement by gemcitabine.
    van Bree C; Rodermond HM; de Vos J; Haveman J; Franken NA
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1504-9. PubMed ID: 15925456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.